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Abstract
Cancer is one of the main healthcare problems in Europe. Although significant progress has
recently been made, long-term survival is still disappointing for most common solid tumours.
The explosion of information has strengthened the need to create and sustain coordinated
interaction between technology, biology, clinical research, clinical practice and health policy. A
simple process based on automatic and passive translation from bench to clinical research and
eventually to the bed side is usually assumed but cannot be taken for granted.
A critical role might be played by Outcome Research (OR), defined as the discipline that describes,
interprets, and predicts the impact of various influences, especially interventions, on final endpoints
(from survival to satisfaction with care) that matter to decision makers (from patients to society at
large), with special emphasis on the use of patient-reported outcomes (PRO).
Recently, under pressure from several parts of society, the FDA, recognizing the need for faster
drug approval, has modified existing regulations and created new rules to allow anti-cancer drugs
to be approved more quickly and, in certain but quite common circumstances, single arm trials and
surrogate endpoints to be used as measures of clinical benefit. In this context, the faster approval
process may lead to drugs being marketed without there being a complete picture of how effective
or safe they are.
The FDA move to speed up drug approval, together with the use of not fully validated surrogate
endpoints, give OR the unique opportunity to help understand the value of drugs that have received
accelerated approval. Despite this opportunity, OR has yet to demonstrate its role in this specific
setting and provide proof of the validity, reliability and added value of its primary endpoint
measures when evaluated in a broader context.
The implementation of lines of OR in the development and evaluation of anti-cancer drugs hinges
upon the availability of specific knowledge, methods, instruments and resources and upon their
appropriate integration in the mainstream of clinical research. In the USA specific interdisciplinary
projects have been launched by the NCI. In Europe there is a lack of such initiatives.
The correct placement of OR in the anti-cancer drug development process will guarantee the
highest possible standard of validity and reliability of OR at European level and better integration
of both translational and outcome research in the mainstream of clinical research into anti-cancer
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drugs, thus speeding up the introduction of the results of patient-oriented translational clinical
research into clinical practice.
Introduction
Cancer is one of the main healthcare problems in Europe.
Although significant progress has recently been made in
understanding the molecular factors underlying the devel-
opment of cancer and the improvements achieved in re-
sponse rates with new drugs, long-term survival is still
disappointing in most solid tumours.
The sequencing of the human genome, the increasing
availability of biotechnological approaches, the explosive
growth of genetics-based biomedical research, have all
rapidly expanded the evidence that large numbers of
genes (or rather the proteins that they code for) may influ-
ence the activity and tolerability of "traditional" drugs".
These facts, together with the introduction of "novel" anti-
cancer drugs based on innovative concepts, have greatly
increased our knowledge, but these gains have not trans-
lated into clinical benefit for patients [1]. This explosion
of information has also strengthened the need to create
and sustain coordinated interaction between technology,
biology, clinical research, clinical practice and health pol-
icy [2].
A simple process based on automatic and passive transla-
tion from bench to clinical research and eventually to the
bed side is usually assumed but cannot be taken for grant-
ed. There are three critical steps from the identification of
new targets to putting a new drug onto the market. The
first concerns the integration of new bio-technologies in a
wider context, the second the translation from basic re-
search to early clinical research, and the third the evalua-
tion of the clinical incremental value of new health
interventions and its prompt delivery to clinical practice.
Ideally, Translational Research (TR) deals with the first
two critical aspects. It is defined as the process of translat-
ing findings derived from basic science to the develop-
ment of a new understanding of the disease mechanism,
diagnosis and therapeutics [1]. It implies a bi-directional
process, utilising knowledge of human biology to develop
and test the feasibility of cancer-relevant interventions in
humans and/or determining the biological basis for ob-
servations made in individuals with cancer or in popula-
tions at risk of cancer. In oncological settings, TR is usually
implemented by creating a "functional" bridge between
scientists working in the field of basic research and re-
searchers involved in the early phases (phase I-II) of clin-
ical research through ad hoc collaborative efforts. Small
but multidisciplinary teams are assembled, the contribu-
tion of each member being based on individual skills. As
a result, it is now increasingly common in early clinical tri-
als to see traditional clinical outcomes (evaluating the ac-
tivity of the drug under evaluation in terms of tumour
shrinking or disease response) used together with biolog-
ical measures (evaluating molecular or cellular critical
events).
The shared efforts of researchers from both basic and re-
search fields aim to identify (namely, to select) as soon as
possible during the Research & Development process po-
tentially effective health interventions (here used in its
broadest sense to indicate molecular assays, imaging tech-
niques, drugs and/or biological products) using a combi-
nation of pre-clinical and clinical measures. Candidate
intervention is then tested further, in a later and confirm-
ative phase of the clinical research (namely, phase III), by
comparing the new health intervention with appropriate
comparators, such as placebo, best supportive care or
well-established active treatments, in terms of safety and
efficacy measures to ensure that the benefits of new drugs
outweigh their risks [3].
In the USA, ad-hoc funding programs have recently been
launched by the NCI to conduct early-stage interventions
aimed at establishing the feasibility or the proof of con-
cept of specific translational approaches in several types of
cancer http://www.nci.nih.gov/. In Europe, the new VI
Framework Program was recently launched to sustain and
enhance the collaboration of the European Centres of Ex-
cellence in several critical research areas, such as genomics
and biotechnology for health http://www.cordis.lu/fp6/
eoi-instruments.
The third critical step regards the passage from clinical re-
search to clinical practice, where the best evidence should
be promptly translated into the best medical care. This
step should incorporate epidemiology and clinical re-
search, as well as health service research. In the case of
drugs, public government agencies, such as the FDA and
EMEA, have the specific responsibility of "governing and
regulating" this critical step by evaluating the quality, safe-
ty and efficacy of new drugs and making beneficial drugs
available as quickly as possible. An important role can
also be attributed to Evidence Based Medicine (EBM), a
movement essentially based on secondary analyses of ex-
isting data (either literature or data) which, by using sys-
tematic review and meta-analysis, aims to identify which
health intervention actually works and should thus be im-
plemented in health care http://www.cochrane.de/co-
chrane/crgs.htm#CENTRES. As EBM essentially uses dataHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/3
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from clinical research to identify, select, appraise and eval-
uate the yield of medical interventions, its value and con-
tribution is essentially related to the availability and
quality of data made available through the process pre-
sented and discussed above.
In addition, the desire to both improve outcomes and
control costs determines the need to know how well effec-
tive therapies work in the practice setting using indicators
that encompass a very broad range of health and non-
health domains.
The need to know the actual value of health interventions
in health care has led to the re-emergence of Outcome Re-
search (OR), a discipline dealing with research methods
and efforts to measure what actually works (effectiveness)
in health care using various complementary outcome
measures, ranging from traditional clinical measures
(symptom control, duration of response, disease progres-
sion or survival) to health-related quality of life and cost
measures [4,5]. Although there is no consensus on its pre-
cise definition, OR is commonly defined as the discipline
that describes, interprets, and predicts the impact of vari-
ous influences, especially interventions, on final end-
points (from survival to satisfaction with care) that matter
to decision makers (from patients to society at large) [6].
The role of OR in the (anti-cancer) drug develop-
ment process
OR is most likely to be successful when it is carried out in
a matrix of basic, clinical, and population activities where
scientists from several but correlated disciplines work to-
gether in pre-planned and integrated projects. In the on-
cological setting, where historically speaking TR, clinical
research and OR are very distinct from each other, they are
seen as distinct and separated fields. TR and OR lie at the
opposite extremes of a continuum, with little or no
chance of interaction and/or cross-fertilization. Clinical
research receives input from basic research and alone, or
in the context of TR projects, focuses on translating find-
ings derived from basic science to the development of new
drugs (with particular interest in research dedicated to ob-
taining experimental results impacting directly on im-
proving approaches to be eventually tested in later
research phases). OR, given its relationship and interac-
tion with health care administrators and/or policy mak-
ers, is more interested in evaluating the effectiveness and
yield of the application in the clinical practice of alterna-
tive therapeutic options made available through the Re-
search & Development process (with particular attention
to the use of humanistic and economic outcomes to com-
pare the value of established treatments) [5,6]. OR, seen
from the health service research perspective, can be de-
fined as research that focuses on identifying variations in
medical procedures and associated health outcomes (i.e.,
evaluation of quality and appropriateness). On the other
hand, when seen from the clinical research perspective,
the ideal place for OR is between clinical research and
clinical practice, in an area usually defined as Phase IV
that is supposed to determine the safety and efficacy of
health interventions in a broader patient population (i.e.,
evaluation of effectiveness).
In the latter context, indeed, OR appears to act in different
ways, being only apparently integrated into mainstream
clinical research. An analysis of the published literature
shows more clearly what OR is not (Phase I, II, or III clin-
ical trials evaluating activity, disease progression or surviv-
al) rather than what it is [7]. As a matter of fact, although
the number of effectiveness studies in oncology incorpo-
rating typical OR endpoints (quality of life and cost meas-
ures) are increasing, very little evidence is available to
answer the question as to whether OR actually affects
drugs policy or practice.
The lack of communication and collaboration between
basic, clinical and outcome research in oncology is partic-
ularly evident in the case of anti-cancer drugs where OR
studies are usually carried out by researchers or institu-
tions which are not directly involved in the production of
pre-clinical or clinical evidence and are under pressure
from policy makers and health administrators concerned
about the appropriate delivery of effective health care at
the lowest cost. However, there are indications that the
present situation could change. Two facts may indeed en-
hance the role of OR in the field of development and eval-
uation of anti-cancer drugs.
Firstly, the American National Cancer Institute has
launched a new quality-of-care initiative, "The Nation's
Investment in Cancer Research" (known informally as the
"Bypass Budget") whose goal is to enhance the state of the
science for defining, measuring, monitoring, and improv-
ing the quality of cancer care, and inform both public- and
private-sector decision making on cancer care delivery,
coverage, regulation, and standards setting http://
plan.cancer.gov/infra/quality.htm. To meet this research
challenge, several activities have been planned and budg-
eted: 1) Define a core set of valid, patient-centred, cancer
outcome measures to enhance our ability to compare in-
terventions across studies and over time. 2) Define a core
set of process measures to identify those interventions
that have been convincingly shown to improve cancer
care outcomes. 3) Build a stronger data and methods "in-
frastructure" for conducting quality of care analyses, in-
cluding studies to determine which interventions improve
patient-valued outcomes. 4) Ensure that therapies shown
to be effective in clinical trials are incorporated into com-
munity practice. 5) Enhance the quality of cancer commu-
nications by gaining a better understanding of theHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/3
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information needs of patients, families, and other deci-
sion makers. It may be noted that some of the above ini-
tiatives (1, 2 and 3) are directly based on the principles of
OR, while the last 2 are more related to Disease and Out-
come Management fields [5].
Secondly, the FDA, recognizing the need for faster drug
approval, has recently modified existing regulations and
created new rules to allow anti-cancer drugs to be ap-
proved more quickly and, in certain but quite common
circumstances, single arm trials and surrogate endpoints
to be used as measures of clinical benefit http://
www.fda.gov/cder/cancer. In this context, there is the pos-
sibility that a faster approval process may lead to drugs be-
ing marketed which are either ineffective or unsafe. In
addition, given the widespread scepticism about the value
of patient-reported outcome measures, tumor-response
based (TRB) measures have frequently been adopted not
only as surrogate endpoints of survival in studies evaluat-
ing "curative" treatments but also as surrogate endpoints
of better/improved (quality of) life, alone or in combina-
tion with ad-hoc composite endpoints (usually referred to
as clinical benefit measures) to support and complement
TRB findings in "palliative" studies. The move to bring
forward an-earlier-than-ideal point along the drug ap-
proval path together with the use of surrogate endpoints
in a very small sample of patients can be considered either
an important step towards ensuring that beneficial drugs
are made available as quickly as possible or a dangerous
shortcut that might jeopardize the consumers' health as
unsafe and ineffective drugs could be marketed and pre-
scribed. On the other hand, it also underscores the need
to validate early findings with well-designed studies to
verify the true clinical benefit in a broader patient popula-
tion, thus emphasizing the role of OR. As OR is placed
downstream the process of accumulating evidence on ac-
tivity, safety and efficacy, it is the disciplines that might
help understand the value of drugs that have received ac-
celerated approval.
Role of PRO measures in the approval of anti-
cancer drugs
Until 1992, marketing approval both in the USA and Eu-
rope required substantial evidence as to safety and effica-
cy, i.e., usually two phase III trials with appropriate
clinical benefit endpoints were necessary to demonstrate
that the drug either prolonged survival or reduced symp-
toms. Starting from December 1992 and then in 1996,
with the FDA Modernization Act, the FDA changed its phi-
losophy about how much and which information is need-
ed in order to make a decision and also introduced
innovations (fast track approach, expedited review and ac-
celerated approval) that both reduced the time for dossier
review and made the use of surrogate endpoints possible
for most anti-cancer drugs http://www.accessda-
ta.fda.gov/scripts/cder/onctools/Accel.cfm. Although effi-
cacy is still formally considered to be synonymous with
clinical benefit and a demonstration of life prolongation
or quality of life improvement with well-designed RCTs is
formally required, on several occasions surrogate end-
points of quality of life and symptomatic clinical benefit,
such as amount and kind of tumour response and non-
validated ad-hoc (compound) clinical benefit measures
(CBM), and single arm trials have actually been accepted
(since 1992, 17% of cases of new anti-cancer drugs used
the accelerated approval, 60% using non-survival end-
points and 28% non-controlled and non-masked trials (R.
Pazdur, FDA-CDER-DOPD, Personal Communication,
2002)).
The EMEA has less explicit regulations on "quick proce-
dures", and expedited "approval" has been used only in
exceptional circumstances (since 1995, only in 2 (10%)
anti-cancer drugs [8]), and has thus been criticised for its
conservative and rigid position [9]. On the other hand,
others have recently raised concerns about the frequent
use of non-inferiority and equivalence design in compar-
ative and randomised trials that allows the approval of
drugs with much uncertainty as to the merits of the drugs
tested [10]. This phenomenon has been particularly evi-
dent for anti-cancer drugs. Drugs approved in the first
years of the EMEA do not meet the expectations generated
by gains in basic knowledge on cancer biology, have not
shown significant improvement in survival, safety or qual-
ity of life, and cost much more than the standard treat-
ments [11].
Surrogate endpoints based on tumour shrinking indica-
tors are used in therapeutic/curative trials to show the
benefits over available therapy as they are considered rea-
sonably likely to predict clinical benefit, namely better
survival, and fewer patients and less time are needed to
complete a trial. However, the reason why surrogate end-
points of quality of life are used instead of formal (psy-
chometric) quality of life instruments is quite different.
Essentially, formal quality of life assessment in clinical tri-
als is considered not only cumbersome, complex and cost-
ly but is also plagued by several unresolved
methodological and statistical problems that make it dif-
ficult to interpret results. In addition, physicians, research-
ers and regulators are sceptical about the value of such
instruments as HR-QoL measures have yet to demonstrate
their added value when used together with traditional
clinical endpoints [12,13]. A recent and still ongoing eval-
uation of the added value of HR-QoL measures in pub-
lished RCTs on advanced breast cancer patients shows
that in the retrieved papers very little information was
available on important methodological aspects, the tools
used were extremely heterogeneous, a large variability in
compliance was reported, there was poor correlation be-Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/3
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tween clinical efficacy and HR-QoL results in most stud-
ies, and HR-QoL data rarely contributed to the choice of
regimen to be recommended [14].
Hence, although the use of surrogate endpoints and non-
validated CBM measures may even be considered a worse
option, in palliative settings quality of life data is usually
collected but approval is still based on surrogate and non-
validated measures [15].
Accordingly, despite the thousands of conceptual and em-
pirical papers published [16] and the genuine recent
growth in cultural interest in measuring the relevant qual-
itative aspects of life most closely related to health and
health care- the so called Health Related Quality of Life
(HRQOL) [17], regulatory agencies such as the FDA and
EMEA do not currently require or recommend the use of
this kind of data to approve new drugs. Neither the EMEA
nor the FDA have published any guidance document on
this issue.
Nevertheless, the two agencies seem to have a slightly dif-
ferent attitude.
The EMEA has included in its recently revised Note for
Guidance for anti-cancer drugs explicit statements regard-
ing the use of HR-QoL instruments in phase II-III studies
http://www.emea.eu.int. Basically, HR-QoL assessment is
accepted and recommended to support tumour shrinking
and/or toxicity and symptoms endpoints, justified case
per case.
In addition, an assessment of all EMEA recommendations
on the use of HRQOL measures in drug approval (recently
up-dated by MAPI, Lyon in the context of the ERIQA
Project http://www.mapi-research-inst.com) has shown
that of the 189 documents retrieved, a few (13/189) con-
tained explicit recommendations regarding the use of HR-
QOL measures in regulatory studies, and in most of these
(12/13) HRQOL measures were considered as secondary
and complementary endpoints [18].
The FDA has neither taken an explicit position nor pub-
lished any guidance document on these issues. In addi-
tion, a comprehensive review of the FDA experience as
regards regulatory drug development strategies since 1949
(and the personal opinions of key persons at the Agency)
suggests a very sceptical and critical opinion. Although
several types of endpoints have served for marketing ap-
proval, including objective response rate, time to disease
progression, palliation of disease-related symptoms or
survival, HRQOL measures have never been prospectively
selected as primary endpoints.
Conclusion
PRO and HR-QoL measures have a potential role in the
Research & Development of anti-cancer drugs but the field
is still plagued by conceptual, methodological and logisti-
cal problems. Simpler but not fully validated alternatives
(TRB, CBM, etc) are appealing but not appropriate in
terms of validity and interpretability. Nevertheless, they
are more acceptable to clinicians, researchers and regula-
tors.
The EMEA considers PRO and HR-QoL as a potential effi-
cacy ("symptomatic" clinical benefit) endpoint but it has
chosen the approach of not publishing general recom-
mendations that would prescribe methodological stand-
ards. Nevertheless, there are several guidance documents
that explicitly discuss the role of HR-QoL measures.
The FDA is more sceptical. However, a multidisciplinary
PRO Working Group, that collaborates with other inde-
pendent international groups to establish principles and
practices for the integration of PRO in the regulatory proc-
ess, was recently set up and draft guidance documents on
HR-QoL will soon be released for comment by the Divi-
sion of Drug Marketing and Advertisement at the CDER
(LB Burke, FDA-CDER-DDMA, Personal Communica-
tion).
Pharmas extensively use PRO measures, mostly on cancer
products. A recent evaluation and preliminary analysis of
the European Public Assessment Report (EPAR) has
shown that in at least 25% of the EPAR reports there is a
claim about HR-QoL, most (25%) in cancer-related prod-
ucts.
The above facts together with the present move to speed
up drug approval together with the use of surrogate end-
points give OR a unique opportunity to demonstrate its
ability to verify the true clinical benefit of drugs in a
broader patient population using appropriate endpoints,
such as PRO measures, and sound design. Although its
potential has been documented by a huge amount of lit-
erature, OR has yet to demonstrate its role in the specific
setting of the research and evaluation of anti-cancer drugs
and provide proof of the validity, reliability and added
value of its primary endpoint measures when evaluated in
a broader context that includes the more traditional (i.e,
clinical) benefit measures that are usually considered pri-
mary endpoints.
The implementation of lines of OR in the development
and evaluation of anti-cancer drugs hinges upon the avail-
ability of specific knowledge, methods, instruments and
resources and upon their appropriate integration in the
mainstream of clinical research. In the USA specific inter-
disciplinary projects have been launched by the NCI. InPublish with BioMed Central    and   every 
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Europe individual areas of expertise and excellence do ex-
ist but the problem is twofold. Firstly, collaboration be-
tween experts from several fields, such as statistics,
epidemiology, psychometrics, economics, decision sci-
ence, etc needs to be integrated and facilitated. Secondly,
appropriate funds need to be made available to imple-
ment such efforts and monitor actual results.
The correct placement of OR in the anti-cancer drug devel-
opment process will guarantee the highest possible stand-
ard of validity and reliability of OR at European level and
better integration of both translational and outcome re-
search in the mainstream of clinical research on anti-can-
cer drugs, thus speeding up the introduction of the results
of patient-oriented translational clinical research into
clinical practice.
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